title: Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
abstract: NSCLC remains one of the most challenging malignancies to treat. Despite the introduction of innovative therapies over the last decade, the 5-year survival of NSCLC is still <20%. Clearly, novel, therapeutic approaches are required. Targeting the immune system to derive meaningful clinical benefit has proved successful in various malignancies in recent years. As a result, there is renewed focus on the use of immunotherapy in lung cancer. In this review, we provide an overview of current immune-modulatory approaches in the treatment of NSCLC.
authors.affiliation: 1.Barts Cancer Institute, Queen Mary, University of London, Charterhouse Square, London, EC1M 6BQ, UK. t.hagemann@qmul.ac.uk.
authors.forename: Fiona
authors.initials: F
authors.lastname: McCarthy
authors.forename: Rozita
authors.initials: R
authors.lastname: Roshani
authors.forename: Jeremy
authors.initials: J
authors.lastname: Steele
authors.forename: Thorsten
authors.initials: T
authors.lastname: Hagemann
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
keywords: immunotherapeutic agents; malignancies; progression-free survival; tumor